HDL cholesterol (HDL-C) is the cholesterol carried in high-density lipoproteins, the smallest and densest lipoprotein particles. HDL takes part in reverse cholesterol transport: it collects excess cholesterol from cells, including macrophages in artery walls, and returns it to the liver for excretion in bile. Low HDL-C is a well-established marker of increased cardiovascular risk. However, raising HDL-C with medicines has not been shown to prevent heart attacks, and extremely high values are not always protective.
Regular aerobic exercise, weight loss and stopping smoking raise HDL-C modestly. Moderate alcohol intake also raises it, but this is not a reason to drink. Oestrogens raise HDL-C, which partly explains higher values in women.
Population studies show a U-shaped relation: risk is higher with low HDL-C, but also not reduced, and possibly increased, at very high levels (above about 2.3–2.5 mmol/L). Genetic studies and trials of HDL-raising drugs (niacin, CETP inhibitors) did not reduce cardiovascular events. For this reason HDL-C is used to estimate risk, but not as a treatment target. Its function, the ability to remove cholesterol, matters more than the measured amount.
HDL-C is used to calculate non-HDL cholesterol (TC − HDL-C, an estimate of all atherogenic particles), the atherogenic coefficient (TC − HDL-C) / HDL-C, and the atherogenic index of plasma log(TG/HDL-C).
Low HDL-C is a signal to address the whole metabolic picture: weight, physical activity, blood glucose, triglycerides and smoking. Your doctor will include HDL-C when estimating your overall cardiovascular risk.
This article is for general information and does not replace a consultation with a doctor. Laboratory results must be interpreted by a physician together with symptoms and other tests.
Published on 1 July 2019